LARIMAR THERAPEUTICS INC (LRMR)
US5171251003 - Common Stock
ChartMill assigns a Buy % Consensus number of 87% to LRMR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 22.85. This target is 253.68% above the current price.
LRMR was analyzed by 11 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about LRMR.
In the previous month the buy percentage consensus was at a similar level.
LRMR was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-03 | Leerink Partners | Initiate | Outperform |
| 2024-03-15 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-03-12 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-02-13 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-02-13 | Citigroup | Maintains | Buy -> Buy |
| 2023-11-17 | Citigroup | Upgrade | Neutral -> Buy |
| 2023-08-15 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-05-18 | Citigroup | Maintains | Neutral -> Neutral |
| 2023-05-17 | Guggenheim | Maintains | Buy -> Buy |
| 2023-05-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-03-15 | Guggenheim | Reiterate | Buy |
| 2022-12-13 | Citigroup | Initiate | Neutral |
| 2022-10-19 | Guggenheim | Initiate | Buy |
| 2022-09-19 | William Blair | Upgrade | Market Perform -> Outperform |
| 2022-09-19 | JMP Securities | Maintains | Market Outperform |
| 2022-02-15 | William Blair | Downgrade | Outperform -> Market Perform |